NeuBase Therapeutics is developing a modular peptide-nucleic acid antisense oligonucleotide platform called PATrOL™ aimed at treating rare genetic diseases. The platform is designed to create systemically deliverable therapeutics that target secondary RNA structures and combine small-molecule tissue distribution with antisense specificity. Initial programs focus on repeat expansion disorders, including Huntington’s disease and myotonic dystrophy. The company announced an oversubscribed financing to support preclinical studies on its platform and lead programs. NeuBase has entered a proposed merger with Ohr Pharmaceutical that would create a public company to advance the PATrOL™ technology. The company is headquartered in Pittsburgh, Pennsylvania.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2019